Contracts › 75A50123C00055
75A50123C00055: The Overall Objective of This Contract Is to Advance the Development, Including U.S. Food and Drug Administration (FDA) Approval, of Atropine Autoinjector for Pediatric Use Using an Improved Version of Rafa Laboratories, Ltd.S (RAFAS) Fda-Approved Si
Awarded to Rafa Laboratories Ltd by Office of Assistant Secretary for Preparedness and Response.
$9.4Mobligated
$14.7Mpotential value
04 August 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50123C00055 |
|---|---|
| Awardee | Rafa Laboratories Ltd |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Offers received | 3 |
| Period of performance | 19 September 2023 to 04 August 2028 |
| Potential end | 01 January 2030 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record